<DOC>
	<DOCNO>NCT00475917</DOCNO>
	<brief_summary>The purpose study determine safe dose XL844 combination gemcitabine , often take , well people cancer tolerate combination gemcitabine XL844 .</brief_summary>
	<brief_title>A Study XL844 Administered Single Agent Combination With Gemcitabine Adults With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . The subject histologically confirm advanced malignancy ( solid tumor lymphoma ) metastatic unresectable , standard curative palliative measure exist longer effective , therapy know prolong survival . 2 . The subject disease assessable tumor marker , physical , radiologic mean . 3 . The subject ≥18 year old . 4 . The subject ECOG ( Eastern Cooperative Oncology Group ) performance status ≤2 . 5 . The subject adequate organ marrow function . 6 . The subject capability understanding informed consent document sign informed consent document . 7 . Sexually active subject ( male female ) must use medically acceptable method contraception course study . 8 . Female subject childbearing potential must negative pregnancy test screening . 9 . If subject receive three prior regimen cytotoxic chemotherapy , two biologic regimen , 3000 cGy &gt; 25 % bone marrow , investigator must discuss sponsor regard subject suitability enrollment . 10 . The subject diagnosis malignancy ( unless nonmelanoma skin cancer , situ carcinoma cervix , malignancy diagnose ≥5 year ago , evidence disease 5 year prior screen study ) . 1 . The subject receive anticancer treatment ( eg , chemotherapy , radiotherapy , immunotherapy , biologic therapy , investigational agent , hormone ) within 14 day prior first dose study drug . 2 . The subject recover Grade ≤1 adverse event ( AEs ) due investigational agent medication administer 30 day prior first dose study drug . 3 . The subject receive radiation &gt; 25 % bone marrow within 30 day XL844 treatment . 4 . The subject primary brain tumor know brain metastasis . 5 . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 6 . The subject pregnant breastfeeding . 7 . The subject know positive human immunodeficiency virus ( HIV ) . 8 . The subject unable unwilling abide study protocol cooperate fully investigator designee . 9 . The subject know allergy hypersensitivity component XL844 formulation gemcitabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Advanced malignancy</keyword>
	<keyword>Solid tumor</keyword>
</DOC>